Starpharma announces DEP cabazitaxel Phase 1/2 Trial

31 January 2018

Morningstar reported on Starpharma's announcement regarding the commencement of its phase 1/2 clinical trial for DEP cabazitaxel having received regulatory and ethics approvals. 

Go to article (external link)


About Starpharma

This document contains Forward Looking Statements

For Further Information


© Starpharma Holdings Limited 2017